NO-naproxen vs. naproxen: Ulcerogenic, analgesic and anti-inflammatory effects

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 1, 1997, Pages 69-79

  Davies, N M ^a   Rooseth A G ^b   Appleyard, C B ^a   Mcknight, W ^a   Del Soldato, P ^c   Calignano, A ^d   Cirino, G ^d   Wallace, J L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c NicOx SA   (France)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIGESTIVE SYSTEM ULCER; DRUG BLOOD LEVEL; GASTROINTESTINAL TOXICITY; INFLAMMATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STOMACH INJURY;

EID: 0031031097     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.115286000.x     Document Type: Article

References (35)

1. Frics JF. NSAID gastropathy: epidemiology. J Musculoskeletal Med 1991; 8: 21-8.
2. Aabakken L, Osnes M. Gastroduodenal lesions induced by naproxen. An endoscopic evaluation of regional differences and a natural course. Scand J Gastroenterol 1990; 25: 1215-22.
3. Uribe A, Johansson C, Slezak P, Rubio C. Ulcerations of the colon associated with naproxen and acetylsalicylic acid treatment. Gastrointest Endosc 1986; 32: 242-4.
4. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties. Gastroenterology 1994; 107: 173-9.
5. Wallace JL, Reuter B, Cicala C, McKnight W, Grisham MB, Cirino G. A diclofenac derivative without ulcerogenic properties. Eur J Pharmacol 1994; 257: 249-55.
6. Reuter B, Cirino G, Wallace JL. Markedly reduced intestinal toxicity of a diclofenac derivative. Life Sci 1994; 55: PLI-8.
7. Wallace JL, Pittman QJ, Cirino G. Nitric oxide releasing NSAIDs: a novel class of GI-sparing anti-inflammatory drugs. In: Proznansky W. ed. New Molecular Approaches to Anti-Inflammatory Therapy. Basle: Birkauser Verlag. 1995: 121-9.
8. Wallace JL. Mechanisms of NSAID-lnduced gastrointestinal damage - potential for development of GI-safe NSAIDs. Can J Physiol Pharmacol 1994; 71: 98-102.
9. Trevethick MA, Clayton NM, Bahl AK, Sanjar S, Strong P. Neutrophil depletion does not prevent indomethacin-induced ulceration of the rat gastric antrum. Agents Actions 1994; 41: C226-7.
10. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993; 17: 641-62.
11. Santucci L, Fiorucci S, Giansanti M, Brunori PM, Di Matteo FM, Morelli A. Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor-α. Gut 1994; 35: 909-15.
12. Appleyard CB, McCafferty D-M, Tigley AW, Swain MG, Wallace JL. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol 1996; 270: G42-8.
13. Wallace JL, Whittle BJR. Role of prostanoids in the protective actions of BW755C on the gastric mucosa. Eur J Pharmacol 1985; 115: 45-52.
14. Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Meth 1983; 65: 55-63.
15. Satoh H, Guth PH, Grossman MI. Role of food in gastrointestinal ulceration produced by indomethacin in the rat. Gastroenterology 1982; 83: 210-5.
16. Foster R, Røseth;seth AG, Fagerhol MK, Peters TJ, Somadsundaram S, Bjarnason I. Indomethacin enteropathy in rats: assessed by a novel granulocytic marker protein (GMP). Proc World Congress Gastroenterol 1995; 1958 (Abstract).
17. Kristinsson J. Røseth;seth AG. Sundset A, Nygaard K, Aadland E, Løberg EM, Paulsen JE, Fagerhol MK. Granulocyte marker protein (GMP) is elevated in stools from rats with azoxymethane induced colon cancer and aberrant crypts. Gastroenterology 1996; 110: A546 (Abstract).
18. Cirino G, Peers SH, Flower RJ, Browning JL, Pepinsky RB. Human recombinant lipocortin 1 has acute local anti-inflammatory properties in the rat paw edema test. Proc Natl Acad Sci USA 1989; 86: 3428-32.
19. Wallace JL, Keenan CM, Granger DN. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am J Physiol 1990: 259: G462-7.
20. Wallace JL, Arfors KE, McKnight GW. A monoclonal antibody against the CD18 leukocyte adhesion molecule prevents indomethacin-induced gastric damage in the rabbit. Gastroenterology 1991; 100: 878-83.
21. Kunkel SL, Remick DG, Stricter RM, Larrick JW. Mechanisms that regulate the production and effects of tumour necrosis factor-α. Crit Rev Immunol 1989; 9: 93-117.
22. Mitchell JA, Cirino G, Akarasereenont P, Wallace JL, Flower RJ, Vane JR. Flurbinitroxybutylester: a novel anti-inflammatory drug devoid of ulcerogenic activity, inhibits cyclo-oxygenase-1 and cyclo-oxgenase-2. Can J Physiol Pharmacol 1994; 72: 270 (Abstract).
23. Meling TR, Aabakken L, Roseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1996; 31: 339-44.
24. Bjarnason I, Hayllar J, Smethurst P, Price A, Gumpel MJ. Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut 1992; 33: 1204-8.
25. May GR, Crook P, Moore PK, Page CP. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br J Pharmacol 1991; 102: 759-63.
26. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-5.
27. Cuzzolin L, Conforti A, Adami A, Lussignoli S, Memestrina F, Del Soldato P, Benoni G, Anti-inflammatory potency and gastrointestinal toxicity of a new compound, NO-naproxen. Pharmacol Res 1995; 31: 61-5.
28. Tseng LF, Xu JY, Pieper GM. Increase of nitric oxide production by L-arginine potentiates i.c.v. administered β-endorphin-induced antinociception in the mouse. Eur J Pharmacol 1992; 212: 301-3.
29. Haley JE, Dickenson AH, Schachter M. Electrophysiological evidence for a role of nitric oxide in prolonged chemical nociception in the rat. Neuropharmacology 1992; 31: 251-8.
30. Rubanyi GM, Ho EH, Cantor EH, Lumma WC, Botelho LH. Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun 1991; 181: 1392-7.
31. Vaananen PM, Meddings JB, Wallace JL. Role of oxygen-derived free radicals in indomethacin-induced gastric injury. Am J Physiol 1991; 261: G470-5.
32. Wallace JL, McKnight W, Del Soldato P, Cirino G. Anti-thrombotic properties of a nitric oxide-releasing, gastric sparing aspirin derivative. J Clin Invest 1995; 96: 2711-8.
33. Brown JF, Hanson PJ, Whittle BJR. Nitric oxide donors increase mucus gel thickness in rat stomach. Eur J Pharmacol 1992; 223: 101-4.
34. Brown JF, Keates AC, Hanson PJ, Whittle BJR. Nitric oxide generators and cGMP stimulate mucus secretion by rat gastric mucosal cells. Am J Physiol 1993; 265: G418-22.
35. Kubes P. Nitric oxide modulates epithelial permeability in the feline small intestine. Am J Physiol 1992; 262: G1138-42.